HTA Submission Trends for EMA-Approved Oncology Medicines 2018-2023
How quickly do oncology medicines move from EMA approval to HTA submission across Europe — and how might this change under the EU HTA Regulation? At ISPOR Europe 2025, [...]
Q4 2025 Newsletter
We're pleased to share the latest CIRS newsletter with you, featuring updates from our recent workshops, global engagements, and research studies advancing medicine regulation and HTA. 🔍 What's Inside: [...]
Assessing Good Review Practices in Zambia Medicines Regulatory Authority – Chisha 2025
Introduction:Â The implementation of Good Review Practices (GRevPs) ensures the timely, high-quality review and enhanced availability to safe, quality, and efficacious medicines. It is important, therefore, that all aspects of [...]
Incentivising Medicine Development for Chronic Diseases – Workshop Report
This CIRS multi-stakeholder workshop examined strategies for incentivising the development of medicines for common chronic diseases.
Regulatory performance of ML3 African NMRAs – Owusu-Asante 2025
Background The World Health Organization (WHO) developed the WHO Global Benchmarking Tool (GBT) to assess and benchmark the drug regulatory systems and practices in national medicines regulatory authorities (NMRAs). [...]
Contribution of the ECOWAS region to the African Medicines Agency
“This book is a must-read for all those with interest in medicines regulation in Africa… It provides timely expert information for consideration and possible adoption during the operationalisation of [...]
CIRS RD Briefing 103 – Review of HTA outcomes and timelines in Australia, Canada, Europe and the UK, 2020-2024
This R&D Briefing presents findings from HTADock, an ongoing CIRS metrics study that collects publicly available data on new active substances (NASs) appraised by 12 HTA agencies in Australia [...]
Incentivising Medicine Development for Chronic Diseases – Workshop Synopsis
This CIRS multi-stakeholder workshop examined strategies for incentivising the development of medicines for common chronic diseases.
How are international regulatory organisations shaping global pharmaceutical policy? Dangy-Caye et al 2025
We’re pleased to share our latest publication in Frontiers in Medicine, developed in collaboration with Sanofi, exploring how international regulatory organisations are shaping global pharmaceutical policy. Data from our [...]
September 2025 Newsletter
Take a look at our latest newsletter, which shares updates on key research activities and publications in the third quarter of 2025. Download newsletter